global+growth

Conceived at the start of the pandemic, COVAX had lofty goals, promising fair and equitable access to Covid-19 vaccines for every country worldwide, and giving them for free to the poorest.

When babies are born in western Kenya, where malaria is rife, many mothers are sent home from the hospital with one all-important baby gift: a bed net treated with insecticide.

Less than a week after Merck and Ridgeback released extraordinary data on the effectiveness of experimental COVID-19 drug molnupiravir, the rush is on to lock up supplies.

The state of Venezuela's already overloaded and crumbling public health system, in which hospitals often lack access to even water, has pushed many to use costly private centers.

High prices and low availability still a major barrier for patients’ access to new and old medicines.

The suggestion was made in the latest report about treatments to be added to the WHO list of essential medicines.

Amnesty international has warned covid-19 developers not to put profits before lives.

As part of their message, the agencies also urged Regeneron to transfer technology used to make its monoclonal antibody to other manufacturers so that lower-cost biosimilar versions could be made more quickly for low and middle-income nations.

In the United States, some health experts have worried that promoting the therapy, which the government covers at a cost of $2,100 per dose, was taking away time and money from the effort to get more Americans vaccinated against Covid.

The health agency urged Regeneron, which holds the patent, to lower the drug’s price and work on equitable distribution worldwide.

New report shows leading Covid-19 vaccine pharma companies fuelling unprecedented human rights crisis.

The treatment has been granted U.S. emergency use authorisation, having gained attention when used to treat former President Donald Trump's COVID-19 illness last year.

This international, cross-sectional survey was developed by investigators from a range of clinical practice settings across low-income to high-income countries, including members of the WHO Essential Medicines Cancer Working Group.

The U.N.-backed vaccine program is so far behind schedule that not even 10 percent of the population in poor countries is fully vaccinated, experts say.

The purchase was to be announced early next week to coincide with the United Nations General Assembly meeting in New York.